GemVax & Kael 

GemVax & KAEL Co., Ltd. specializes in manufacturing chemical filtration systems and gas purification units, primarily for the semiconductor industry. The company operates through two main segments: Environmental Pollution Control and Bio Business. Its Environmental Pollution Control division focuses on creating essential filters for semiconductor and display fabrication processes, in addition to developing equipment for air quality management and odor prevention. Concurrently, the Bio Business division is dedicated to advancing its innovative telomerase-derived peptide drug, GV1001, through preparations for domestic and international Phase 2 and 3 clinical trials. These trials are designed to address various conditions, including Alzheimer's disease, benign prostatic hyperplasia, and progressive supranuclear palsy. Founded on March 10, 1998, GemVax & KAEL Co., Ltd. is headquartered in Daejeon, South Korea.